AHA advertorial: 340B program advances health for patients and communities
As drug prices continue to rise, the 340B drug pricing program continues to help hospitals expand access to comprehensive health services, including lifesaving prescription drugs for those in need who may not be able to afford them, writes AHA President and CEO Rick Pollack in the Wall Street Journal.
“It is in the best interest of all to keep the 340B program strong so that our nation’s patients and communities can continue to receive the high-quality care and services on which they depend,” the advertorial adds.
Related News Articles
Headline
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a report detailing findings from an investigation…
Headline
The AHA April 18 filed friend-of-the-court briefs in three cases in support of Louisiana's 340B contract pharmacy law that prohibits drug companies from…
Headline
A Minnesota state court April 15 dismissed a lawsuit filed by PhRMA challenging the state’s law protecting 340B pricing for contract pharmacy arrangements. The…
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Health and Human Services said its decision to prevent drug companies from implementing a 340B rebate model “was within its statutory…
Headline
The AHA this week filed a number of friend-of-the-court briefs in cases before the U.S. District Court for the District of Columbia, urging the court to uphold…